十年磨一剑:肝细胞癌诊疗新进展  

New progress in the diagnosis and treatment of hepatocellular carcinoma:a decade of grinding sword

作　　者：刘红艳[1] 王坤远 樊蓉[1] 侯金林[1,2] Liu Hongyan;Wang Kunyuan;Fan Rong;Hou Jinlin(Hepatology Unit and Department of Infectious Diseases,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;Hepatology Unit,Shenzhen Hospital,Southern Medical University,Shenzhen 518133,China)

机构地区：[1]南方医科大学南方医院感染内科肝病中心,广州510515 [2]南方医科大学深圳医院肝病中心,深圳518133

出　　处：《中华肝脏病杂志》2021年第2期111-115,共5页Chinese Journal of Hepatology

基　　金：深圳市医药卫生"三名工程"高层次医学团队项目(SZSM201911001)。

摘　　要：肝细胞癌(HCC)是全世界范围内发病率和死亡率极高的恶性肿瘤之一,肿瘤晚期预后欠佳。近十年来,HCC治疗领域出现的新进展涵盖了外科手术、消融、经血管介入、外放射治疗、系统治疗等方面,其中尤以靶向和免疫检查点药物等系统治疗方面的进展尤为突出,显著提高了肝癌患者的五年生存率。此外,针对肝癌患者的管理,尤其是高风险人群的筛查和多学科协作诊疗,提升了肝癌的早诊率和改善了总体治疗效果。考虑到我国国情和现有治疗手段的发展情况,在未来,精准识别高危HCC人群,提高HCC早诊率,制定个性化的HCC治疗策略,将是降低HCC死亡率的最有效手段。Globally,hepatocellular carcinoma(HCC)is one of the most highly morbid,fatal,and malignant tumors,with a poor prognosis in advanced stage.In the past decade,new advances have been emerged in the field of HCC therapy,including surgery,ablation,transvascular intervention,external radiotherapy,and systemic therapy.Among them,systemic treatments,particularly targeted and immune checkpoint drugs have made outstanding progress,significantly improving the five-year survival rate of liver cancer patients.In addition,the management of liver cancer patients,especially the screening management and multidisciplinary collaborative diagnosis and treatment of high-risk populations,has significantly increased the early diagnosis rate and improved the overall treatment efficacy.Considering our country's condition and the development of existing treatment,the most effective strategy to reduce HCC mortality in the future is to accurately identify high-risk populations,increase the early diagnosis rate,and formulate personalized treatment strategies.

关 键 词：肝细胞癌 筛查 早期诊断 多学科协作诊疗 系统治疗 

分 类 号：R735.7[医药卫生—肿瘤]